Dana E. Rathkopf

Active 2007–2026

91
Papers
27,059
Citations
54
h-index
86
i10-index

Citations

Citations per year for Dana E. Rathkopf1992: 1 citations1994: 1 citations1999: 1 citations2003: 1 citations2004: 1 citations2007: 1 citations2009: 6 citations2010: 15 citations2011: 51 citations2012: 35 citations2013: 82 citations2014: 142 citations2015: 225 citations2016: 275 citations2017: 340 citations2018: 443 citations2019: 1,143 citations2020: 1,310 citations2021: 1,440 citations2022: 1,119 citations2023: 903 citations2024: 1,511 citations2025: 712 citations2026: 27 citations1993: no citations, so this year is not shown1995–1998: no citations, so these years are not shown2000–2002: no citations, so these years are not shown2005–2006: no citations, so these years are not shown2008: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,452 citing papers, 26.8% of this breakdownChina: 1,249 citing papers, 9.7% of this breakdownUnited Kingdom: 824 citing papers, 6.4% of this breakdownGermany: 667 citing papers, 5.2% of this breakdownCanada: 646 citing papers, 5% of this breakdownItaly: 624 citing papers, 4.9% of this breakdownFrance: 493 citing papers, 3.8% of this breakdownAustralia: 423 citing papers, 3.3% of this breakdownSpain: 408 citing papers, 3.2% of this breakdownJapan: 382 citing papers, 3% of this breakdownNetherlands: 368 citing papers, 2.9% of this breakdownSwitzerland: 339 citing papers, 2.6% of this breakdown
0%26.8%Other 23.2%

Fields

  • Medicine67.5%
  • Biochemistry, Genetics and Molecular Biology26.6%
  • Immunology and Microbiology2%
  • Engineering1.4%
  • Computer Science1%
  • Chemistry0.2%
  • Other1.3%

Topics

  • Prostate Cancer Treatment and Research16.2%
  • Prostate Cancer Diagnosis and Treatment7%
  • Cancer Genomics and Diagnostics5.9%
  • Radiopharmaceutical Chemistry and Applications3.9%
  • Cancer Cells and Metastasis3.3%
  • Cancer, Lipids, and Metabolism2.8%
  • Other60.9%

Coauthors

All papers

Open in search
  1. OncoKB: A Precision Oncology Knowledge Base

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio Omuro, Michael A. Postow, Dana E. Rathkopf, Alexander N. Shoushtari, Neerav Shukla, Martin H. Voss, Ederlinda Paraiso, Ahmet Zehir, Michael F. Berger, Barry S. Taylor, Leonard B. Saltz, Gregory J. Riely, Marc Ladanyi, David M. Hyman, José Baselga, Paul Sabbatini, David B. Solit, Nikolaus Schultz - JCO Precision Oncology 2017 cited by 2,698

  2. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 3,701

  3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  4. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 3,031

  5. Organoid Cultures Derived from Patients with Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen B. Solomon, James A. Eastham, Ping Chi, Brett S. Carver, Mark A. Rubin, Howard I. Scher, Hans Clevers, Charles L. Sawyers, Yu Chen - Cell 2014 cited by 1,588

  6. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Howard Gurney, Elizabeth Hovey, Anthony M. Joshua, Matos Marco, Gavin Marx, Michelle Morris, Siobhan Ng, David Pook, Shahneen Sandhu, Ali Tafreshi, Thean Hsiang Tan, Tsvetanka Tosheva, Livia Andrade, Felipe Melo Cruz, Luiza Dib Batista Bugiato Faria, J. M. L. Figueiredo, Fábio Franke, Andrea Juliana Gomes, Ariel Galapo Kann, Celio Kussumoto, Suelen Patrícia dos Santos Martins, André M. Murad, Hélio Pinczowski, Giovani Thomaz Pioner, Luís Ferreira Pires, Daniel D’Almeida Preto, Gisele Marinho dos Santos, Eduardo Silva, Jamile Silva, Luciano de Souza Viana, Karina Vianna, Adriano Augusto Peclat de Paula, Zhiwen Chen, Kim Chi, Urban Emmenegger, Neil Fleshner, Sunil Parimi, Fred Saad, Francisco Vera-Badillo, Hongqian Guo, Hong Luo, Lulin Ma, Mingxing Qui, Wei Xue, Guo Yonglian, Lei Li, Jinxian Pu, Song Zheng, Qing Zou, Miloš Broďák, Milan Hora, Vladimír Šámal, Vladimír Študent, J Vaňásek, Emmanuelle Bompas, Philippe Barthélémy, Delphine Borchiellini, Aude Fléchon, Hakim Mahammedi, Guilhem Roubaud, Antoine Thiery-Vuillemin, Diégo Tosi, Dominique Spaëth, Carole Hélissey, Martin Boegemann, Susan Feyerabend, Eva Hellmis, Martin Schostak, Gerhardt Attard, Anna Lydon and 141 more - Journal of Clinical Oncology 2023 cited by 319

  7. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf - New England Journal of Medicine 2012 cited by 2,795

  8. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Howard I. Scher - JAMA Oncology 2018 cited by 663

  9. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 1,354

  10. Treatment of Advanced Prostate Cancer

    Authors: , , - Annual Review of Medicine 2019 cited by 727

  11. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2020 cited by 254

  12. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 cited by 242

  13. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 199

  14. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barry S. Taylor, Marc Ladanyi, Diana Mandelker, Liying Zhang, Victor E. Reuter, Philip W. Kantoff, David B. Solit, Michael F. Berger, Charles L. Sawyers, Nikolaus Schultz, Howard I. Scher - JCO Precision Oncology 2017 cited by 531

  15. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  16. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

    Authors: , , , , , , , , , , , , , , , , , , , , - European Urology 2016 cited by 419

  17. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Andrea Sboner, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 591

  18. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  19. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet 2010 cited by 1,084

  20. Accelerating precision medicine in metastatic prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2020 cited by 77

  21. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2024 cited by 66

  22. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Management and Research 2019 cited by 85

  23. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 67

  24. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 106